Danaher Co. (NYSE:DHR) Shares Sold by Forsta AP Fonden

Forsta AP Fonden cut its position in shares of Danaher Co. (NYSE:DHR) by 7.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 157,522 shares of the conglomerate’s stock after selling 13,100 shares during the quarter. Forsta AP Fonden’s holdings in Danaher were worth $39,357,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Jupiter Asset Management Ltd. grew its holdings in shares of Danaher by 0.6% during the 2nd quarter. Jupiter Asset Management Ltd. now owns 216,834 shares of the conglomerate’s stock worth $54,176,000 after purchasing an additional 1,345 shares during the period. Hazlett Burt & Watson Inc. increased its position in shares of Danaher by 4,761.9% in the second quarter. Hazlett Burt & Watson Inc. now owns 1,021 shares of the conglomerate’s stock worth $256,000 after acquiring an additional 1,000 shares in the last quarter. LPL Financial LLC raised its stake in shares of Danaher by 9.0% in the 2nd quarter. LPL Financial LLC now owns 353,217 shares of the conglomerate’s stock valued at $88,251,000 after acquiring an additional 29,043 shares during the period. Biltmore Family Office LLC raised its stake in shares of Danaher by 13.1% in the 2nd quarter. Biltmore Family Office LLC now owns 1,811 shares of the conglomerate’s stock valued at $453,000 after acquiring an additional 210 shares during the period. Finally, Studio Investment Management LLC boosted its position in Danaher by 4.4% during the 2nd quarter. Studio Investment Management LLC now owns 1,390 shares of the conglomerate’s stock worth $348,000 after purchasing an additional 59 shares during the period. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Danaher

In other news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the transaction, the chief executive officer now owns 97,983 shares of the company’s stock, valued at $27,435,240. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock worth $11,042,433 over the last 90 days. Insiders own 11.10% of the company’s stock.

Danaher Stock Performance

Shares of DHR stock opened at $271.98 on Thursday. The stock has a market capitalization of $196.43 billion, a price-to-earnings ratio of 46.10, a PEG ratio of 4.38 and a beta of 0.83. Danaher Co. has a one year low of $182.09 and a one year high of $281.70. The company’s 50-day simple moving average is $263.20 and its 200-day simple moving average is $256.22. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter last year, the business posted $2.05 EPS. Danaher’s quarterly revenue was down 2.9% compared to the same quarter last year. Equities analysts anticipate that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.40%. Danaher’s dividend payout ratio is presently 18.31%.

Analyst Upgrades and Downgrades

Several research firms have commented on DHR. Barclays raised their price objective on Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 24th. Leerink Partners boosted their price target on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Wells Fargo & Company initiated coverage on shares of Danaher in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price objective for the company. The Goldman Sachs Group boosted their target price on shares of Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $300.00 price target on shares of Danaher in a report on Friday, September 6th. Seven research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $278.94.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.